Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: Comparison with sirolimus-eluting stents

J. S. Kim, I. K. Jang, J. S. Kim, T. H. Kim, M. Takano, T. Kume, N. W. Hur, Y. G. Ko, D. Choi, M. K. Hong, Y. Jang

Research output: Contribution to journalArticle

95 Citations (Scopus)


Objective: To evaluate the vascular response at 9 months after zotarolimus-eluting stent (ZES; Endeavor) implantation using optical coherence tomography (OCT). These findings were compared with those after implantation of a sirolimus-eluting stent (SES; Cypher Select). Design: Cross-sectional observational study with prospective OCT registry. Setting: Nine months after ZES or SES implantation. Patients and methods: A total of 68 patients (32 ZES and 36 SES) underwent OCT at 9 months after stent implantation. The neointima hyperplasia (NIH) thickness inside each strut and percentage of NIH area at every 1 mm cross section were measured. Main outcome measurement: The degree of neointimal coverage and the prevalence of malapposition at 9 months after ZES and SES implantation using OCT. Results: The mean (SD) NIH thickness (251.2 (110.0) mm vs 85.5 (53.3) μm, p<0.001) and percentage of NIH area (27.9 (9.1)% vs 11.2 (7.1)%, p<0.001) were significantly greater in ZES than in SES. The prevalence of uncovered strut as well as malapposed strut was significantly lower in ZES than in SES (0.3% vs 12.3%, p<0.001 and 0.08% vs 2.6%, p<0.001). Thrombus was not observed in ZES (0.0% in ZES vs 27.8% in SES, p = 0.001). Conclusions: Neointimal coverage in ZES was almost complete and malapposition was very rare at 9-months' follow-up.

Original languageEnglish
Pages (from-to)1907-1912
Number of pages6
Issue number23
Publication statusPublished - 2009 Dec 1


All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this